Eli Lilly announces Verzenio survival benefit

Breast Cancer Ireland applauds this new breakthrough as Eli Lilly and Company has announced that its CDK4 & 6 inhibitor Verzenio (abemaciclib) has been found to significantly extend life in women with HR+, HER2- advanced breast cancer. To read more about this, click the link below:

http://www.pharmatimes.com/news/eli_lilly_announces_verzenio_survival_benefit_1295959?fbclid=IwAR1_QRfAIuOZ6HgZ6zzOEb5exIPc1l9v9h0WIrN8X1HkAX8d2HYbwW1GHi0

Share This Article

Breast Cancer Ireland

Lower Ground Floor
Breast Cancer Ireland
77 Merrion Square South
Dublin 2

Email: info@breastcancerireland.com
Tel: 00353-1-5160331

Charity No: Chy 19926

Breast Cancer Ireland has been incorporated as Breast Cancer Ireland CLG, trading as: Breast Cancer Ireland

X